CONCLUSION:
Clinicians should consider the potential association of Daunorubicin with SJS, administer it with caution and observe patients closely for potentially dangerous cutaneous reaction and treat it as an oncologic emergency. If multi-drug regimen chemotherapy is employed, one must administer the drugs with caution and all subsequently developing cutaneous reactions must promptly be evaluated with a high index of suspicion for SJS.